Hepion Pharmaceuticals, Inc.
HEPA
$0.2975
$0.01294.53%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 1.01% | -20.99% | -40.17% | -22.54% | -21.31% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -83.35% | -58.20% | -39.97% | -60.77% | -26.14% |
| Operating Income | 83.35% | 58.20% | 39.97% | 60.77% | 26.14% |
| Income Before Tax | 86.51% | 53.78% | 72.12% | 56.08% | -18.29% |
| Income Tax Expenses | 100.00% | -- | -- | -- | 85.82% |
| Earnings from Continuing Operations | 86.01% | 53.78% | 72.12% | 78.48% | -62.37% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 86.01% | 53.78% | 72.12% | 78.48% | -62.37% |
| EBIT | 83.35% | 58.20% | 39.97% | 60.77% | 26.14% |
| EBITDA | 83.32% | 58.12% | 39.89% | 60.95% | 26.12% |
| EPS Basic | 91.15% | 73.59% | 81.60% | 83.83% | 3.85% |
| Normalized Basic EPS | 77.05% | 73.58% | 60.63% | 55.90% | 36.11% |
| EPS Diluted | 91.15% | 73.59% | 81.60% | 83.83% | 3.85% |
| Normalized Diluted EPS | 77.05% | 73.58% | 60.63% | 55.90% | 36.11% |
| Average Basic Shares Outstanding | 58.12% | 75.00% | 51.63% | 33.20% | 15.62% |
| Average Diluted Shares Outstanding | 58.12% | 75.00% | 51.63% | 33.20% | 15.62% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |